FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1950302841> ?p ?o ?g. }

• W1950302841 abstract "Long-acting muscarinic antagonists (LAMA), a class of drugs with proven effectiveness in chronic obstructive pulmonary disease (COPD), are being considered as an add-on option for adults with asthma whose condition is uncontrolled on inhaled corticosteroids (ICS). It is important to assess the safety and efficacy of LAMA add-on as an alternative to the prolonged use of higher doses of ICS, which are known to cause undesirable side effects in some people.To compare the effects of adding a LAMA to any dose of ICS versus increasing the dose of ICS, for uncontrolled asthma in adults.We searched the Cochrane Airways Group Specialised Register (CAGR) from its inception in 1995 to April 2015, imposing no restriction on language of publication. We also handsearched trial registries, reference lists of primary studies and existing reviews, as well as manufacturers' websites.We looked for parallel or cross-over randomised controlled trials lasting at least 12 weeks, in which adults whose asthma was not well controlled on ICS alone were randomised to treatment with LAMA add-on to ICS or with an increased dose of ICS. Trials were excluded if patients were taking long-acting beta2-agonists during the study period.Two review authors independently screened the searches and extracted data from studies meeting all the inclusion criteria. We used Covidence to manage duplicate screening, data extraction and risk of bias judgements, and to form a consensus where discrepancies arose. We used standard methods expected by The Cochrane Collaboration.The pre-specified primary outcomes were exacerbations requiring a course of oral corticosteroids (OCS), effects on quality of life and serious adverse events.One cross-over randomised controlled trial met the inclusion criteria. The trial was performed in 210 patients with moderate to severe asthma and compared the use of the LAMA tiotropium bromide with double dose beclomethasone (an ICS) using a cross-over design and 14-week treatment periods.Compared with people taking a double dose of ICS, fewer people taking a LAMA add-on had an exacerbation requiring treatment with OCS (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.22 to 1.43) or an exacerbation resulting in emergency department admission (OR 0.49, 95% CI 0.09 to 2.77), but the confidence intervals for both outcomes did not exclude the possibility that double dose ICS was more effective. Serious adverse events and exacerbations requiring hospitalisation occurred in similarly low numbers of people taking each treatment, but confidence intervals were too wide to suggest that the two treatment options were equivalent.Asthma-related quality of life was similar in both treatment groups (mean difference (MD) in change from baseline 0.10, 95% CI - 0.07 to 0.27). Those taking LAMA add-on scored slightly better on a scale measuring asthma control than those increasing their ICS dose (MD in change from baseline - 0.18, 95% CI - 0.34 to - 0.02), although the difference was clinically small. Evidence was deemed low quality for both quality of life and asthma control.There was moderate-quality evidence that participants' trough forced expiratory volume in one second (FEV1) was 100 mL better when taking LAMA add-on than with increased ICS dose (MD in change from baseline 0.10, 95% CI 0.03 to 0.17).Only one randomised trial was found, comparing tiotropium add-on to increased dose beclomethasone. Differences between the treatments were too small or imprecise to understand whether adding a LAMA to ICS is safer or more effective than increasing the dose of ICS, and there is a possibility of carry-over effects due to the study's cross-over design. LAMA add-on may lead to more improvement in lung function (FEV1) than an increased dose of ICS.The results of this review, alongside pending results from related reviews assessing the use of LAMA against other treatments, will help to define the role of these drugs in asthma management, and this review should be updated as results from future trials emerge. Studies assessing the role of LAMA add-on should be longer and include a double-ICS treatment arm so that the results can be interpreted in the context of the guideline-recommended treatment options that are available to physicians." @default.
• W1950302841 created "2016-06-24" @default.
• W1950302841 creator A5046288882 @default.
• W1950302841 creator A5051660368 @default.
• W1950302841 creator A5057028908 @default.
• W1950302841 date "2015-08-24" @default.
• W1950302841 modified "2023-10-14" @default.
• W1950302841 title "Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma" @default.
• W1950302841 cites W1631769030 @default.
• W1950302841 cites W1962391690 @default.
• W1950302841 cites W2009191674 @default.
• W1950302841 cites W2020414852 @default.
• W1950302841 cites W2057557604 @default.
• W1950302841 cites W2071270488 @default.
• W1950302841 cites W2087717750 @default.
• W1950302841 cites W2100595093 @default.
• W1950302841 cites W2105863984 @default.
• W1950302841 cites W2106566051 @default.
• W1950302841 cites W2115817977 @default.
• W1950302841 cites W2116395845 @default.
• W1950302841 cites W2119147796 @default.
• W1950302841 cites W2126325768 @default.
• W1950302841 cites W2146374592 @default.
• W1950302841 cites W2152149480 @default.
• W1950302841 cites W2162154826 @default.
• W1950302841 cites W2330255005 @default.
• W1950302841 cites W4253771981 @default.
• W1950302841 cites W4323254566 @default.
• W1950302841 doi "https://doi.org/10.1002/14651858.cd011397.pub2" @default.
• W1950302841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26301488" @default.
• W1950302841 hasPublicationYear "2015" @default.
• W1950302841 type Work @default.
• W1950302841 sameAs 1950302841 @default.
• W1950302841 citedByCount "26" @default.
• W1950302841 countsByYear W19503028412015 @default.
• W1950302841 countsByYear W19503028412016 @default.
• W1950302841 countsByYear W19503028412017 @default.
• W1950302841 countsByYear W19503028412018 @default.
• W1950302841 countsByYear W19503028412019 @default.
• W1950302841 countsByYear W19503028412020 @default.
• W1950302841 countsByYear W19503028412021 @default.
• W1950302841 countsByYear W19503028412022 @default.
• W1950302841 countsByYear W19503028412023 @default.
• W1950302841 crossrefType "journal-article" @default.
• W1950302841 hasAuthorship W1950302841A5046288882 @default.
• W1950302841 hasAuthorship W1950302841A5051660368 @default.
• W1950302841 hasAuthorship W1950302841A5057028908 @default.
• W1950302841 hasBestOaLocation W19503028412 @default.
• W1950302841 hasConcept C126322002 @default.
• W1950302841 hasConcept C168563851 @default.
• W1950302841 hasConcept C2776042228 @default.
• W1950302841 hasConcept C2776719499 @default.
• W1950302841 hasConcept C2776780178 @default.
• W1950302841 hasConcept C2780911369 @default.
• W1950302841 hasConcept C71924100 @default.
• W1950302841 hasConceptScore W1950302841C126322002 @default.
• W1950302841 hasConceptScore W1950302841C168563851 @default.
• W1950302841 hasConceptScore W1950302841C2776042228 @default.
• W1950302841 hasConceptScore W1950302841C2776719499 @default.
• W1950302841 hasConceptScore W1950302841C2776780178 @default.
• W1950302841 hasConceptScore W1950302841C2780911369 @default.
• W1950302841 hasConceptScore W1950302841C71924100 @default.
• W1950302841 hasIssue "8" @default.
• W1950302841 hasLocation W19503028411 @default.
• W1950302841 hasLocation W19503028412 @default.
• W1950302841 hasLocation W19503028413 @default.
• W1950302841 hasLocation W19503028414 @default.
• W1950302841 hasLocation W19503028415 @default.
• W1950302841 hasOpenAccess W1950302841 @default.
• W1950302841 hasPrimaryLocation W19503028411 @default.
• W1950302841 hasRelatedWork W1984797374 @default.
• W1950302841 hasRelatedWork W2346277111 @default.
• W1950302841 hasRelatedWork W2767263702 @default.
• W1950302841 hasRelatedWork W2886338893 @default.
• W1950302841 hasRelatedWork W2894474424 @default.
• W1950302841 hasRelatedWork W3047434665 @default.
• W1950302841 hasRelatedWork W3201115502 @default.
• W1950302841 hasRelatedWork W4200437369 @default.
• W1950302841 hasRelatedWork W4230984066 @default.
• W1950302841 hasRelatedWork W4248150072 @default.
• W1950302841 hasVolume "2015" @default.
• W1950302841 isParatext "false" @default.
• W1950302841 isRetracted "false" @default.
• W1950302841 magId "1950302841" @default.
• W1950302841 workType "article" @default.